Nicotinamide drives T cell activation in the mammary tumor microenvironment.
J Transl Med
; 20(1): 251, 2022 06 03.
Article
en En
| MEDLINE
| ID: mdl-35659314
ABSTRACT
Nicotinamide (NAM, a variant of vitamin B3) has recently been shown to accelerate the activation of human CD4+ and CD8+ T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also express multiple markers of late-stage activation. Taken together, these findings lend additional support to the notion that the antineoplastic effects of NAM involve at least some degree of restored cancer immunosurveillance.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Niacinamida
/
Microambiente Tumoral
Límite:
Animals
Idioma:
En
Revista:
J Transl Med
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos